CareDx, Inc.

DB:1K9 Stock Report

Market Cap: €789.3m

CareDx Valuation

Is 1K9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1K9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1K9 (€16.02) is trading below our estimate of future cash flow value (€18.42)

Significantly Below Future Cash Flow Value: 1K9 is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1K9?

Key metric: As 1K9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1K9. This is calculated by dividing 1K9's market cap by their current revenue.
What is 1K9's PS Ratio?
PS Ratio2.4x
SalesUS$379.81m
Market CapUS$916.26m

Price to Sales Ratio vs Peers

How does 1K9's PS Ratio compare to its peers?

The above table shows the PS ratio for 1K9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.6x
BIO3 Biotest
2xn/a€1.4b
BIO3 Biotest
1.8xn/a€1.4b
FYB Formycon
7.3x25.50%€348.7m
7V0 Darwin
3.5x27.59%€96.0m
1K9 CareDx
2.4x11.24%€916.3m

Price-To-Sales vs Peers: 1K9 is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (3.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1K9's PS Ratio compare vs other companies in the DE Biotechs Industry?

15 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.3x14.0%
1K9 CareDx
 2.4x11.24%US$916.26m
BIO3 Biotest
1.8xn/aUS$1.63b
BIO3 Biotest
2xn/aUS$1.58b
1K9 2.4xIndustry Avg. 7.3xNo. of Companies14PS01632486480+
15 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.3x21.8%
1K9 CareDx
 2.4x95.11%US$916.26m
No more companies

Price-To-Sales vs Industry: 1K9 is good value based on its Price-To-Sales Ratio (2.4x) compared to the European Biotechs industry average (7.3x).

Price to Sales Ratio vs Fair Ratio

What is 1K9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1K9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio1.6x

Price-To-Sales vs Fair Ratio: 1K9 is expensive based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1K9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€16.02
€21.21
+32.46%
10.01%€23.95€17.96n/a5
Mar ’27€15.72
€20.33
+29.31%
12.03%€23.72€16.94n/a6
Feb ’27€17.10
€18.86
+10.32%
13.79%€22.29€15.43n/a5
Jan ’27€16.13
€19.58
+21.40%
15.47%€23.83€15.32n/a6
Dec ’26€15.28
€19.32
+26.41%
20.79%€24.22€12.11n/a6
Nov ’26€12.50
€18.81
+50.49%
20.55%€24.12€12.06n/a6
Oct ’26€12.22
€18.48
+51.25%
20.55%€23.69€11.85n/a6
Sep ’26€11.54
€18.75
+62.52%
20.55%€24.05€12.03n/a6
Aug ’26€10.63
€23.15
+117.87%
23.71%€34.51€16.39n/a6
Jul ’26€16.40
€26.14
+59.39%
26.35%€35.05€16.65n/a6
Jun ’26€14.44
€26.27
+81.96%
25.27%€35.88€17.04n/a7
May ’26€15.74
€24.36
+54.74%
23.45%€35.43€16.83n/a6
Apr ’26€16.23
€29.74
+83.27%
18.91%€36.61€21.51n/a7
Mar ’26€20.07
€31.38
+56.35%
18.32%€38.45€22.59€15.727
Feb ’26€21.92
€31.50
+43.69%
18.00%€38.34€23.01€17.107
Jan ’26€20.00
€32.30
+61.48%
13.08%€37.26€26.08€16.136
Dec ’25€23.34
€32.30
+38.37%
13.08%€37.26€26.08€15.286
Nov ’25€20.20
€32.61
+61.42%
13.97%€36.74€25.72€12.506
Oct ’25€27.74
€30.40
+9.59%
17.97%€35.76€23.25€12.226
Sep ’25€27.65
€30.40
+9.94%
17.97%€35.76€23.25€11.546
Aug ’25€23.46
€27.11
+15.54%
7.40%€29.65€24.09€10.634
Jul ’25€14.32
€16.31
+13.94%
16.12%€20.22€12.86€16.404
Jun ’25€12.36
€15.18
+22.83%
23.28%€20.23€11.04€14.444
May ’25€7.59
€12.16
+60.28%
14.60%€14.03€9.35€15.745
Apr ’25€9.60
€11.44
+19.20%
13.10%€13.84€9.23€16.235
Mar ’25€9.75
€11.44
+17.36%
13.10%€13.84€9.23€20.075
€22.2
Fair Value
27.9% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/09 13:02
End of Day Share Price 2026/03/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CareDx, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC